
Episode 132 - February 21, 2025
Biotech Hangout
00:00
Bluebird's Battle: A Biotech Struggle
This chapter examines the recent acquisition of Bluebird by private equity firms as it grapples with financial woes and competition from Chinese biotech firms. The discussion delves into the challenges of turning innovative gene therapy advances into successful commercial products and the potential impact on patient care. Amidst skepticism regarding profitability and management decisions, there remains cautious optimism for Bluebird's future under new ownership.
Transcript
Play full episode